8q24 copy number gains and expression of the C-MYC mRNA stabilizing protein CRD-BP in primary breast carcinomas

• Type: Article in International Scientific Journal
• Date: 2003

Authors

Ioannidis, P (Author) Other; Mahaira, L (Author) Other; Papadopoulou, A (Author) Other; Manuel R Teixeira (Author) ICBAS; Heim, S (Author) Other; Andersen, JA (Author) Other; Evangelou, E (Author) Other; Dafni, U (Author) Other; Pandis, N (Author) Other; Trangas, T (Author) Other

Journal

Title: International Journal of Cancer

Vol. 104

Pages: 54-59

ISSN: 0020-7136

Publisher: Wiley-Blackwell

Indexing

ISI Web of Knowledge - 47 Citations

Scopus - 48 Citations

Other information

Authenticus ID: P-000-HD6

DOI: 10.1002/ijc.10794

Abstract (EN): The coding region determinant binding protein (CRD-BP) was isolated by virtue of its high affinity to the c-myc mRNA coding region stability determinant and shown to shield this message from nucleolytic attack, prolonging its half -life. CRD-BP is normally expressed during fetal life but is also activated de novo, in tumors. Considering that aberrant CRD-BP expression may represent an additional mechanism interfering with c-myc regulation, we screened I 18 primary breast carcinomas for CRD-BP expression, 60 of which had also been analyzed by comparative genomic hybridization (CGH). Copy number gains encompassing 8q24, the chromosome band that contains the c-myc locus, were detected in 48.3% (29/60) of tumors, whereas gains involving band 17q21, which contains the CRD-BP locus, were observed in 18.3% (11/60) of tumors. CRD-BP expression was detected in 58.5% (69/118) of tumors, implying mechanisms of activation alternative to gene amplification. Altogether, some 75% of the tumors had alterations pertaining to c-myc since they either harbored 8q24 gains and/or expressed CRD-BP. Significant associations were detected between CRD-BP expression and the absence of estrogen receptors (p = 0.005) and between the presence of 8q24 gains and an increased number of genomic changes as measured by CGH (p = 0.0017). Tumors were divided into 4 groups according to CRD-SP expression and 8q24 gains. The odds for tumors having both characteristics to be classified as poorly differentiated (grade III vs. grade I and II) were 19.6 times the corresponding odds for tumors neither expressing CRD-BP nor harboring 8q24 gains. For tumors either harboring 8q24 gains only or expressing CRD-BP alone, the corresponding odds were 6.4 and 3, respectively. (C) 2002 Wiley-Liss, Inc.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 6